title: Impact of Metformin on Advanced Pancreatic Cancer Survival: Too Little, Too Late?
abstract: Metformin offers no survival advantage in patients with metastatic pancreatic cancer. Despite promising experimental evidence suggesting an antitumor effect of metformin, its impact on the survival of advanced pancreatic cancer is likely very limited. Future studies may need to consider its role in early-stage pancreatic cancer. See related article by Reni et al., p. 1076.
authors.affiliation: Division of Gastroenterology and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. yangy@mail.med.upenn.edu.
authors.forename: Yu-Xiao
authors.initials: YX
authors.lastname: Yang
authors.affiliation: Division of Gastroenterology and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Abramson Cancer Center and Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
authors.forename: Anil K
authors.initials: AK
authors.lastname: Rustgi
mesh_terms: D006801:Humans; D008687:Metformin / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms
chemical_list: D008687:Metformin